Heidelberg Pharma AG (XTER:HPHA) Net Income From Continuing Operations : €-13.06 Mil (TTM As of May. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Heidelberg Pharma AG's net income from continuing operations for the three months ended in May. 2024 was €-4.17 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in May. 2024 was €-13.06 Mil.

Heidelberg Pharma AG Net Income From Continuing Operations Historical Data

The historical data trend for Heidelberg Pharma AG's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Net Income From Continuing Operations Chart

Heidelberg Pharma AG Annual Data

Trend

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

Net Income From Continuing Operations

Get a 7-Day Free Trial

-10.15

-18.37

-26.14

-19.70

-20.35

Heidelberg Pharma AG Quarterly Data
	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24
Net Income From Continuing Operations	Get a 7-Day Free Trial															-9.39	0.11	-4.51	-4.49	-4.17

Heidelberg Pharma AG Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in May. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-13.06 Mil.

Heidelberg Pharma AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

HPHA:Germany

Address

Gregor-Mendel-Street 22, Ladenburg, DEU, 68526

Website

https://www.heidelberg-pharma.com

Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.

Executives

Prof. Dr. Andreas Pahl

Board of Directors

Heidelberg Pharma AG Headlines

No Headlines